See the published version of this article at BMC Pulmonary Medicine.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Evaluation of sensitivity and specificity of CanPatrolTM technology for detection of circulating tumor cells in patients with non-small cell lung cancer
Haidong Wang
Third Military Medical University Southwest Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4409-4339
Shixin Zhang
Army Medical University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Pulmonary Medicine.
Background : The early diagnosis of non-small cell lung cancer is of great significance to the prognosis of patients. However, traditional histopathology and imaging screening have certain limitations. Therefore, new diagnostical methods are urgently needed for the current clinical diagnosis.
Objectives: To evaluate of sensitivity and specificity of CanPatrol TM technology for detection of circulating tumor cells in patients with non-small cell lung cancer (NSCLC).
Methods: CTCs in the peripheral blood of 98 patients with NSCLC and 38 patients with benign pulmonary diseases were collected by the latest typing of CanPatrol TM detection technology. A 3-year follow-up was preformed to observe their recurrence and metastasis. Kruskal-Wallis test was used to compare multiple groups of data, Mann-Whitney U test was used to compare data between the two groups, and ROC curve analysis was used to obtain the critical value. The COX risk regression and Kaplan-Meier survival analysis were performed in the 63 NSCLC patients who were effectively followed up.
Results: The epithelial, epithelial-mesenchymal and total CTCs were significantly higher in NSCLC patients than that in patients with benign lung disease (P < 0.001). The mesenchymal CTCs of NSCLC patients was slightly higher than that of benign lung diseases (P = 0.013). The AUC of the ROC curve of the total CTCs was 0.837 (95% CI: 0.76-0.914), and the cut-off value corresponding to the most approximate index was 0.5 CTCs/5 ml, at which point the sensitivity was 81.6% and the specificity was 86.8%. COX regression analysis revealed that clinical stage was correlation with patient survival (P = 0.006), while gender, age and smoking were not (P > 0.05). After excluding the confounders of staging, surgery, and chemotherapy, Kaplan-Meier survival analysis showed that patients in stage IIIA with CTCs ≥ 0.5 had significantly lower DFS than those with CTCs < 0.5 (P = 0.022).
Conclusion : CTC positive can well predict the recurrence of NSCLC patients. CanPatrol TM technology has good sensitivity and specificity in detecting CTCs in peripheral blood of NSCLC patients, and has certain value for clinical prognosis evaluation.
Keywords
NSCLC, CTCs, CanPatrolTM, Sensitivity, Specificity
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
No comments provided
Editor assigned
On 02 Oct, 2020
Submission checks complete
On 01 Oct, 2020
Editor invited
On 01 Oct, 2020
No comments provided
Editor assigned
On 24 Sep, 2020
Submission checks complete
On 23 Sep, 2020
Editor invited
On 23 Sep, 2020
No comments provided
Editor assigned
On 22 Sep, 2020
Submission checks complete
On 21 Sep, 2020
Editor invited
On 21 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 10 Sep, 2020
Reviewer #1 agreed
On 09 Sep, 2020
Review #1 received
Received 09 Sep, 2020
Reviewers invited
Invitations sent on 06 Sep, 2020
Editor assigned
On 31 Aug, 2020
Submission checks complete
On 30 Aug, 2020
Editor invited
On 30 Aug, 2020
Version 2
Posted 10 Jul, 2020
No comments provided
Editorial decision: Minor revision
On 12 Aug, 2020
Review #1 received
Received 10 Aug, 2020
Reviewer #2 agreed
On 27 Jul, 2020
Review #2 received
Received 27 Jul, 2020
Reviewers invited
Invitations sent on 12 Jul, 2020
Reviewer #1 agreed
On 12 Jul, 2020
Editor assigned
On 10 Jul, 2020
Submission checks complete
On 09 Jul, 2020
Editor invited
On 09 Jul, 2020
No comments provided
Editorial decision: Major revision
On 05 Jun, 2020
Review #1 received
Received 01 Jun, 2020
Review #2 received
Received 22 May, 2020
Reviewer #2 agreed
On 18 May, 2020
Reviewer #3 agreed
On 18 May, 2020
Reviewer #1 agreed
On 10 May, 2020
Reviewers invited
Invitations sent on 09 May, 2020
Editor assigned
On 04 May, 2020
First submitted
On 03 May, 2020
Submission checks complete
On 03 May, 2020
Editor invited
On 03 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pulmonology
Learn more about our company.
This preprint is under consideration at BMC Pulmonary Medicine. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Evaluation of sensitivity and specificity of CanPatrolTM technology for detection of circulating tumor cells in patients with non-small cell lung cancer
Haidong Wang
Third Military Medical University Southwest Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4409-4339
Shixin Zhang
Army Medical University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
No comments provided
Editor assigned
On 02 Oct, 2020
Submission checks complete
On 01 Oct, 2020
Editor invited
On 01 Oct, 2020
No comments provided
Editor assigned
On 24 Sep, 2020
Submission checks complete
On 23 Sep, 2020
Editor invited
On 23 Sep, 2020
No comments provided
Editor assigned
On 22 Sep, 2020
Submission checks complete
On 21 Sep, 2020
Editor invited
On 21 Sep, 2020
No comments provided
Editorial decision: Minor revision
On 10 Sep, 2020
Reviewer #1 agreed
On 09 Sep, 2020
Review #1 received
Received 09 Sep, 2020
Reviewers invited
Invitations sent on 06 Sep, 2020
Editor assigned
On 31 Aug, 2020
Submission checks complete
On 30 Aug, 2020
Editor invited
On 30 Aug, 2020
Version 2
Posted 10 Jul, 2020
No comments provided
Editorial decision: Minor revision
On 12 Aug, 2020
Review #1 received
Received 10 Aug, 2020
Reviewer #2 agreed
On 27 Jul, 2020
Review #2 received
Received 27 Jul, 2020
Reviewers invited
Invitations sent on 12 Jul, 2020
Reviewer #1 agreed
On 12 Jul, 2020
Editor assigned
On 10 Jul, 2020
Submission checks complete
On 09 Jul, 2020
Editor invited
On 09 Jul, 2020
No comments provided
Editorial decision: Major revision
On 05 Jun, 2020
Review #1 received
Received 01 Jun, 2020
Review #2 received
Received 22 May, 2020
Reviewer #2 agreed
On 18 May, 2020
Reviewer #3 agreed
On 18 May, 2020
Reviewer #1 agreed
On 10 May, 2020
Reviewers invited
Invitations sent on 09 May, 2020
Editor assigned
On 04 May, 2020
First submitted
On 03 May, 2020
Submission checks complete
On 03 May, 2020
Editor invited
On 03 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pulmonology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published version at BMC Pulmonary Medicine.
Background : The early diagnosis of non-small cell lung cancer is of great significance to the prognosis of patients. However, traditional histopathology and imaging screening have certain limitations. Therefore, new diagnostical methods are urgently needed for the current clinical diagnosis.
Objectives: To evaluate of sensitivity and specificity of CanPatrol TM technology for detection of circulating tumor cells in patients with non-small cell lung cancer (NSCLC).
Methods: CTCs in the peripheral blood of 98 patients with NSCLC and 38 patients with benign pulmonary diseases were collected by the latest typing of CanPatrol TM detection technology. A 3-year follow-up was preformed to observe their recurrence and metastasis. Kruskal-Wallis test was used to compare multiple groups of data, Mann-Whitney U test was used to compare data between the two groups, and ROC curve analysis was used to obtain the critical value. The COX risk regression and Kaplan-Meier survival analysis were performed in the 63 NSCLC patients who were effectively followed up.
Results: The epithelial, epithelial-mesenchymal and total CTCs were significantly higher in NSCLC patients than that in patients with benign lung disease (P < 0.001). The mesenchymal CTCs of NSCLC patients was slightly higher than that of benign lung diseases (P = 0.013). The AUC of the ROC curve of the total CTCs was 0.837 (95% CI: 0.76-0.914), and the cut-off value corresponding to the most approximate index was 0.5 CTCs/5 ml, at which point the sensitivity was 81.6% and the specificity was 86.8%. COX regression analysis revealed that clinical stage was correlation with patient survival (P = 0.006), while gender, age and smoking were not (P > 0.05). After excluding the confounders of staging, surgery, and chemotherapy, Kaplan-Meier survival analysis showed that patients in stage IIIA with CTCs ≥ 0.5 had significantly lower DFS than those with CTCs < 0.5 (P = 0.022).
Conclusion : CTC positive can well predict the recurrence of NSCLC patients. CanPatrol TM technology has good sensitivity and specificity in detecting CTCs in peripheral blood of NSCLC patients, and has certain value for clinical prognosis evaluation.
Figure 1
Figure 2
Figure 3